Decursin Derivative Composition Targeting Progerin–Lamin A Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aging-related diseases such as Hutchinson Gilford progeria syndrome (HGPS) and Werner syndrome lack a fundamental solution, and existing pharmaceutical compositions have side effects, with a need for a compound that effectively inhibits progerin-Lamin A binding.
Innovation Solution
A pharmaceutical composition containing a compound represented by Chemical Formula 1 or its pharmaceutically acceptable salt, specifically (7S)-(+)-8,8-dimethyl-7-(3-phenyl-allyoxy)-7,8-dihydro-6H-pyrano[3,2-g]chromen-2-one (SLC-D011), which inhibits progerin-Lamin A binding and is used in formulations like injections, granules, and cosmetic compositions to treat aging-related diseases and improve skin wrinkles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If progeria is treated by inhibiting farnesylation of progerin or removing farnesylated Lamin A using autophage, then progerin expression is reduced, but side effects occur
Solution Approach 1:
The patent uses a small molecule compound (Formula 1) as an intermediary that binds to progerin and prevents its interaction with Lamin A, rather than directly inhibiting farnesylation or inducing autophagy. This intermediary approach achieves progerin suppression with reduced side effects by targeting the protein-protein interaction interface instead of cellular machinery
Solution Approach 2:
The compound in Formula 1 changes the binding parameters between progerin and Lamin A by forming a stable complex that prevents pathological interaction. The molecular structure parameters of the compound are optimized to achieve selective binding to progerin with high affinity, thereby reducing side effects while maintaining effective progerin suppression
2Reliability
If Lamin A progerin binding is inhibited to treat aging-related diseases, then nuclear deformation is reduced, but fundamental treatment has not been achieved
Solution Approach 1:
The patent extracts and targets the specific pathological interaction between progerin and Lamin A using a small molecule compound. By taking out this specific binding interaction as the therapeutic target, the invention achieves fundamental treatment of the underlying cause of nuclear deformation and aging-related diseases, rather than addressing secondary effects
3Reliability
If existing pharmaceutical compositions are used for aging-related diseases, then some therapeutic effect is achieved, but side effects limit their use
Solution Approach 1:
The patent employs a small molecule compound (Formula 1) that acts as a temporary but effective inhibitor of progerin-Lamin A binding. The compound is designed to be metabolically stable yet eventually cleared, providing sustained therapeutic effect without long-term accumulation and side effects. The molecular structure includes metabolizable groups that allow safe elimination
Data Source
Figure 1A~1F
Figure 2A~2F
Figure 3A~3E
AI summary
The present invention relates to a novel decursin derivative and a composition for preventing or treating an aging-related disease comprising the same as an active ingredient. The novel decursin derivative has exhibited an excellent effect of inhibiting progerin expression and excellent effect of inhibiting binding between progerin and lamin A, and it has been confirmed that the novel decursin derivative prolongs the survival period of animal models in which progerin was induced. Therefore, a compound of the present invention can be effectively used for the prevention or treatment of aging-related diseases such as progeria, etc.